Serum levels of CXCL2 and CXCL5 exhibited race-specific differences, while CCL23 showed both race- and cancer-specific differences supporting the potential contribution of systemic chemokines in differential outcomes among races in association with prostate cancer. Here, CXCL2 is linked to prostate cancer.